Terms: = Germ cell tumor AND MITF, WS2A, ENSG00000187098, 4286 AND Treatment
198 results:
1. Anti-melanogenic effect of exosomes derived from human dermal fibroblasts (BJ-5ta-Ex) in C57BL/6 mice and B16F10 melanoma cells.
Lee JM; Lee JO; Kim Y; Jang YN; Yeon Park A; Kim SY; Han HS; Kim BJ; Yoo KH
Pigment Cell Melanoma Res; 2024 Mar; 37(2):232-246. PubMed ID: 37758515
[TBL] [Abstract] [Full Text] [Related]
2. Dynamical modeling of proliferative-invasive plasticity and IFNγ signaling in melanoma reveals mechanisms of PD-L1 expression heterogeneity.
Subhadarshini S; Sahoo S; Debnath S; Somarelli JA; Jolly MK
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37678920
[TBL] [Abstract] [Full Text] [Related]
3. The Assessment of Anti-Melanoma Potential of Tigecycline-cellular and Molecular Studies of cell Proliferation, Apoptosis and Autophagy on Amelanotic and Melanotic Melanoma cells.
Rok J; Kowalska J; Rzepka Z; Stencel D; Skorek A; Banach K; Wrześniok D
Cells; 2023 Jun; 12(12):. PubMed ID: 37371034
[TBL] [Abstract] [Full Text] [Related]
4. 6-Methylcoumarin Promotes Melanogenesis through the PKA/CREB, MAPK, AKT/PI3K, and GSK3β/β-Catenin Signaling Pathways.
Kim T; Kang JK; Hyun CG
Molecules; 2023 Jun; 28(11):. PubMed ID: 37299026
[TBL] [Abstract] [Full Text] [Related]
5. Reversing vemurafenib-resistance in primary melanoma cells by combined romidepsin and type I IFN treatment through blocking of tumorigenic signals and induction of immunogenic effects.
Fragale A; Stellacci E; Romagnoli G; Licursi V; Parlato S; Canini I; Remedi G; Buoncervello M; Matarrese P; Pedace L; Ascione B; Pizzi S; Tartaglia M; D'Atri S; Presutti C; Capone I; Gabriele L
Int J Cancer; 2023 Sep; 153(5):1080-1095. PubMed ID: 37293858
[TBL] [Abstract] [Full Text] [Related]
6. Trametinib-Resistant Melanoma cells Displaying mitf
Koziej P; Kluszczynska K; Hartman ML; Czyz M
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175614
[TBL] [Abstract] [Full Text] [Related]
7. An adverse tumor-protective effect of IDO1 inhibition.
Kenski JCN; Huang X; Vredevoogd DW; de Bruijn B; Traets JJH; Ibáñez-Molero S; Schieven SM; van Vliet A; Krijgsman O; Kuilman T; Pozniak J; Loayza-Puch F; Terry AM; Müller J; Logtenberg MEW; de Bruijn M; Levy P; Körner PR; Goding CR; Schumacher TN; Marine JC; Agami R; Peeper DS
Cell Rep Med; 2023 Feb; 4(2):100941. PubMed ID: 36812891
[TBL] [Abstract] [Full Text] [Related]
8. Miglitol, an Oral Antidiabetic Drug, Downregulates Melanogenesis in B16F10 Melanoma cells through the PKA, MAPK, and GSK3β/β-Catenin Signaling Pathways.
Kim HM; Hyun CG
Molecules; 2022 Dec; 28(1):. PubMed ID: 36615308
[TBL] [Abstract] [Full Text] [Related]
9. Melanogenesis and the Targeted Therapy of Melanoma.
Li C; Kuai L; Cui R; Miao X
Biomolecules; 2022 Dec; 12(12):. PubMed ID: 36551302
[TBL] [Abstract] [Full Text] [Related]
10. Targeting Wnt/β-Catenin Signaling Exacerbates Ferroptosis and Increases the Efficacy of Melanoma Immunotherapy via the Regulation of mitf.
Wang H; Zhang H; Chen Y; Wang H; Tian Y; Yi X; Shi Q; Zhao T; Zhang B; Gao T; Guo S; Li C; Guo W
Cells; 2022 Nov; 11(22):. PubMed ID: 36429010
[TBL] [Abstract] [Full Text] [Related]
11. Uterine Leiomyosarcoma Masquerading as a Malignant Perivascular Epithelioid cell tumor: A Diagnostic Challenge.
Natsume T; Yoshida H; Nishikawa T; Kikkawa N; Naka T; Kobayashi-Kato M; Tanase Y; Uno M; Ishikawa M; Kato T
Int J Surg Pathol; 2023 Aug; 31(5):778-784. PubMed ID: 36310451
[TBL] [Abstract] [Full Text] [Related]
12. Cooperative induction of receptor tyrosine kinases contributes to adaptive MAPK drug resistance in melanoma through the PI3K pathway.
Alver TN; Heintz KM; Hovig E; Bøe SL
Cancer Rep (Hoboken); 2023 Feb; 6(2):e1736. PubMed ID: 36251678
[TBL] [Abstract] [Full Text] [Related]
13. Imperatorin Positively Regulates Melanogenesis through Signaling Pathways Involving PKA/CREB, ERK, AKT, and GSK3β/β-Catenin.
Kim T; Hyun CG
Molecules; 2022 Oct; 27(19):. PubMed ID: 36235048
[TBL] [Abstract] [Full Text] [Related]
14. Whole transcriptome and proteome analyses identify potential targets and mechanisms underlying tumor treating fields against glioblastoma.
Xu S; Luo C; Chen D; Tang L; Chen L; Liu Z
Cell Death Dis; 2022 Aug; 13(8):721. PubMed ID: 35982032
[TBL] [Abstract] [Full Text] [Related]
15. Cutaneous and uveal melanoma: two different cancers in therapeutic needs.
Bertolotto C
C R Biol; 2021 Nov; 344(3):219-231. PubMed ID: 35786627
[TBL] [Abstract] [Full Text] [Related]
16. Innate immune receptor signaling induces transient melanoma dedifferentiation while preserving immunogenicity.
Thier B; Zhao F; Stupia S; Brüggemann A; Koch J; Schulze N; Horn S; Coch C; Hartmann G; Sucker A; Schadendorf D; Paschen A
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35697379
[TBL] [Abstract] [Full Text] [Related]
17. Candidate therapeutic agents in a newly established triple wild-type mucosal melanoma cell line.
Shi C; Gu Z; Xu S; Ju H; Wu Y; Han Y; Li J; Li C; Wu J; Wang L; Li J; Zhou G; Ye W; Ren G; Zhang Z; Zhou R
Cancer Commun (Lond); 2022 Jul; 42(7):627-647. PubMed ID: 35666052
[TBL] [Abstract] [Full Text] [Related]
18. Novel GSK-3 kinase inhibitor Pym-5 induces GSK-3β rather than GSK-3α-dependent melanogenesis in murine melanoma cells.
Jia Q; Tao L; Zhou Y; Song L; Wei Z; Lu T; Woodgett JR; Lu Y
J Dermatol Sci; 2022 Jun; 106(3):170-180. PubMed ID: 35641396
[TBL] [Abstract] [Full Text] [Related]
19. Silibinin promotes melanogenesis through the PKA and p38 MAPK signaling pathways in melanoma cells.
Uto T; Ohta T; Katayama K; Shoyama Y
Biomed Res; 2022; 43(2):31-39. PubMed ID: 35431290
[TBL] [Abstract] [Full Text] [Related]
20. Discoidin Domain Receptor 2 orchestrates melanoma resistance combining phenotype switching and proliferation.
Sala M; Allain N; Moreau M; Jabouille A; Henriet E; Abou-Hammoud A; Uguen A; Di-Tommaso S; Dourthe C; Raymond AA; Dupuy JW; Gerard E; Dugot-Senant N; Rousseau B; Merlio JP; Pham-Ledart A; Vergier B; Tartare-Deckert S; Moreau V; Saltel F
Oncogene; 2022 Apr; 41(18):2571-2586. PubMed ID: 35322197
[TBL] [Abstract] [Full Text] [Related]
[Next]
